At Okairos we are pioneering the development of T-cell based vaccines for major infectious diseases, including hepatitis C, malaria, respiratory syncytial virus and influenza, as well as cancer.
We are a clinical-stage company at the forefront of a new generation of potential medicines, aiming to unlock the as yet untapped significant potential of our proprietary adenovirus vectors in both prophylactic and therapeutic vaccines.
We have the strongest CD8 T-cell responses in the industry to date, a robust pipeline, an experienced management team and a knowledgeable board of directors.
